148 results about "Mice brain" patented technology

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention discloses application of burdock root polysaccharide in preparation of a medicine for treating cognitive impairment, and belongs to the technical field of traditional Chinese medicines. Experiments prove that the burdock root polysaccharide can improve cognitive impairment and autonomous exploration ability of D-galactose induced cognitive impairment model mice, increase the activity of superoxide dismutase in serum of the mice, reduce the content of malondialdehyde, reduce the content of hippocampus interleukin-1beta and tumor necrosis factor-alpha in brains of the mice, and improve the cognitive impairment activity of the mice. According to the present invention, with the composition, the loss of the neuron in the hippocampal region of the cognitive impairment model mouse can be reduced so as to achieve the neuron protection effect, such that the good treatment effect on the cognitive impairment can be provided, and the new approach is provided for the development of the cognitive impairment-related drug.

The invention discloses application of a plant lactobacillus CCFM1357 to conversion of anthocyanin to generate various active metabolites, inhibition of a cGAS-STING pathway and enhancement of improvement of brain aging, and belongs to the technical field of microorganisms and the technical field of medicines. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention have the following effects: (1) a marker for relieving D-gal induced mouse brain senescence and a marker for relieving D-gal induced mouse brain senescence; (2) promoting and relieving D-gal induced mouse histopathologic characterization; (3) relieving D-gal induced mouse neuroinflammation; (4) relieving behavioral characterization of the D-gal induced aging mouse; and (5) a cGAS-STING signal channel is inhibited. The phytobacterium plantarum CCFM1357 fermented anthocyanin and the compound preparation thereof provided by the invention can be used for a product for relieving brain aging, and have a huge application prospect.

The invention belongs to the field of medicines, and discloses application of a stress-induced stem cell extract in treatment of cerebral apoplexy. The inventor finds that stem cells are cultured under proper stress conditions through screening, and the separated stem cell extract (also known as Alritoin) can increase the axon length and dendritic length of normal primary neurons and is beneficial to growth and conduction of nerve fibers; in a pdMCAO model, the volume of cerebral infarction in the acute stage of ischemia of a mouse can be remarkably reduced, the neurological function score can be improved, and a relatively good improvement trend is achieved in the aspect of cognition; in the acute stage of cerebral ischemia reperfusion, the pharmaceutical composition has remarkable effects on reducing the cerebral infarction volume of a mouse, reducing relative edema and improving the neurological function, and is relatively long in medication time window; in a cerebral ischemia reperfusion model, the trend of improving local cerebral blood flow is shown. The allitoin is expected to be developed into a promising drug for cerebral apoplexy, especially a drug for treating ischemic cerebral apoplexy.

The invention discloses application of walnut peptide in preparation of a medicine for treating or preventing cognitive impairment of diabetes mellitus. The preparation process of the walnut peptide is as follows: after walnut protein is subjected to enzymolysis by alkaline protease, the molecular weight cut-off is 1t; and separating by using a 3kDa ultrafiltration tube to obtain the walnut peptide. The walnut peptide can effectively reduce the blood sugar level of a diabetic model mouse, regulate the disorder effect of blood fat, relieve brain tissue oxidative damage and hippocampal neuroinflammation damage of the diabetic model mouse, and improve learning and memory damage. The compound can be used for preparing medicines for treating or preventing cognitive impairment of diabetes mellitus.

The invention belongs to the field of biological medicines, and provides a construction method of a photochemically induced mouse cerebral ischemia model, which comprises the following steps: S1, inducing anesthesia of a mouse, and ensuring that the mouse is continuously in an anesthesia state; s2, in the lateral position of the mouse, unhairing and disinfecting the face on one side, and cutting from the face of the mouse to expose the proximal end position of the M3 segment of the middle cerebral artery of the mouse or the cross point of reverse extension lines of branch blood vessels of the middle cerebral artery; s3, injecting a photosensitizer into the mouse, and after the photosensitizer circulates uniformly in the body of the mouse, irradiating the proximal end of the M3 segment of the middle cerebral artery or the cross point of the reverse extension line of the branch blood vessel of the middle cerebral artery after laser focusing; s4, after laser irradiation is finished, the skin is sutured, anesthesia is stopped, and the wound of the mouse is coated with an analgesic. The model obtained by the construction method of the photochemically induced mouse cerebral ischemia model provided by the invention has a larger infarct volume, and the infarct invades the subcortical brain region, so that the pathological characteristics of ischemic brain tissues are more obvious.

The invention discloses application of eugenin in preparation of a medicine for treating cerebral arterial thrombosis, and belongs to the technical field of medicines. An in-vivo middle cerebral artery occlusion model is adopted, after reperfusion is conducted for 24 h, the cerebral infarction volume and movement coordination function defect of a mouse are detected to evaluate the treatment effect of eugenin, and activation of microglial cells and survival of neuronal cells are observed through immunofluorescence to clarify the action way of eugenin. Pharmacological activity shows that eugenin can obviously reduce the cerebral infarction volume of a model mouse, improve pathological damage of cells and promote recovery of a motion coordination function, and the action way of eugenin is to promote survival of neuronal cells and inhibit activation of microglial cells. Research results indicate that eugenin has the effect of resisting cerebral arterial thrombosis and can be used as a candidate medicine for developing the cerebral arterial thrombosis resisting medicine.

The invention relates to the technical field of animal experiments, and discloses a mouse cerebral infarction model establishment method and system.The mouse cerebral infarction model establishment method comprises the following steps that in the mouse cerebral infarction model operation process, mouse operation data are obtained in real time, and anomaly detection feedback is carried out, specifically, the anomaly detection feedback comprises generation of a suture insertion anomaly signal; if the suture insertion abnormal signal is generated, performing similarity analysis of curve shapes and characteristics in combination with a historical database of the mouse cerebral infarction model surgery, and constructing a significant similar curve set; and analyzing the effectiveness of the mouse cerebral infarction model operation in the significant similar curve set, and determining the adjustability of the current mouse cerebral infarction operation abnormality. According to the method, the pressure and depth data are collected in real time, the anomaly detection coefficient is calculated, immediate early warning of the suture insertion anomaly is carried out, whether adjustment is needed or an operation is ended is analyzed after early warning, the subjectivity of traditional experience judgment is reduced, and the success rate of the operation is increased.

The invention provides an application of phosphatidylcholine 36: 1 in prevention and treatment of senescence cognitive impairment, and particularly relates to an application of phosphatidylcholine 36: 1 or a pharmaceutical composition containing phosphatidylcholine 36: 1 in preparation of drugs for prevention and / or treatment of senescence cognitive impairment. The phosphatidylcholine 36: 1 can improve the level of superoxide dismutase and glutathione peroxidase in the brain of the mouse and reduce the lipid oxidation level at the same time. After the phosphatidylcholine 36: 1 is used for treatment, the levels of inflammatory factors interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in the brain are obviously reduced. Meanwhile, neurotransmitter disorder in brains of senescent mice can be remarkably improved. After qRT-PCR analysis is carried out in the brain of a mouse, it is found that after phosphatidylcholine 36: 1 treatment, the senescence gene level is remarkably reduced, the pro-apoptosis gene level is remarkably reduced, and the anti-apoptosis gene level is remarkably increased. And after in vitro administration of phosphatidylcholine 36: 1 to mouse hippocampal neuronal cells, no cytotoxicity is found. Therefore, the phosphatidylcholine 36: 1 can be used for preventing and treating senescence cognitive impairment.

The invention discloses a method for detecting mouse brain nucleus activation based on manganese-enhanced magnetic resonance imaging, and belongs to the field of image processing, and the method comprises the steps: converting an acquired mouse head manganese-enhanced magnetic resonance image into an NIFTI format, and enabling the direction and voxel size of the image to be consistent with a standard mouse brain map template; performing offset field correction on the image; loading a PLKA-nnUNet model, carrying out image segmentation on the image, outputting a binary brain mask, and extracting an individual mouse brain image from the image after bias field correction; carrying out image registration and intensity normalization; for each registered individual mouse brain image, calculating relaxation rate mean values of four hippocampal subregions of the mouse brain R1 image, wherein the relaxation rate mean values are used for quantitatively comparing mouse brain activation conditions; and carrying out voxel-level statistical test on the registered and normalized individual mouse brain images to identify brain regions with intensity differences among different experimental conditions. According to the method, the dependence on professional operation is reduced.

The invention belongs to the field of tumor drugs, and particularly relates to application of an adeno-associated virus vector overexpressing Semaphorin 3G in preparation of drugs for treating brain glioma. The AAV-SEMA3G can effectively reduce the growth speed of brain glioma of mice and prolong the survival time of tumor-bearing mice, and can be particularly used for preparing drugs for treating brain glioma and the like. The invention discloses an application of AAV-SEMA3G in preparation of a medicine for treating brain glioma.

The present invention belongs to the field of biomedical technology and specifically relates to the use of Akkermansia muciniphila in ameliorating and treating cerebral malaria caused by Plasmodium berghei. This study evaluated the efficacy of Akkermansia muciniphila alone or in combination with adjuvant drugs (dihydroartemisinin, rapamycin, and atorvastatin) in ameliorating and treating cerebral malaria in a mouse cerebral malaria model. The results suggest that the bacteria, whether used alone or in combination with other drugs, effectively improved mouse behavior, immune pathological damage to various organs, reduced parasitemia, and prolonged mouse survival, demonstrating its effectiveness in treating cerebral malaria in mice compared to using the drugs alone. Because Akkermansia muciniphila is a common probiotic in the human gut, the three drugs used in this study (dihydroartemisinin, rapamycin, and atorvastatin) are all currently in clinical use. Clinical translation for the treatment of human cerebral malaria caused by Plasmodium falciparum is highly feasible and can also shorten the conversion time. This study proposes for the first time the concept of bacterial-drug synergy, whereby probiotics can complement drug treatments, and provides a solution for the treatment of human cerebral malaria based on this concept.

The invention discloses application of micromolecule RNA in preparation of a medicine for treating depression, and belongs to the technical field of biomedicine. The invention finds that the small molecule RNA comprising the nucleotide sequence shown as ACAUUCA has a remarkable anti-depression effect. The micromolecule RNA, especially miR-181a-5p, acts on a chronic social contusion stress (CSDS) model mouse of which the expression level of the mPFC brain region is remarkably reduced, and the miR-181a-5p level of the mPFC brain region of the CSDS model mouse can be improved, so that the pathological change and depression-like behaviors of the CSDS mouse can be remarkably improved. According to the application of the small-molecule RNA in preparation of the anti-depression medicine, the small-molecule RNA can recover mitochondrial functions of neurons in a CSDS model mouse mPFC brain region, repair neuronal synaptic injury and improve and recover depression-like behaviors of depression diseases.

The present invention relates to the field of biomedicine technology, and specifically discloses a dicyanoisophorone fluorescent probe for detecting brain β-amyloid protein, its preparation method and application. The fluorescent probe of the present invention is based on the dicyanoisophorone structure, and a probe with dual recognition sites is formed by introducing a carbamate group and an N,N-dimethylamino group. Compared with probes with a single recognition site, probes with dual recognition sites have a more sensitive fluorescent response to Aβ aggregates in vitro and show higher binding affinity and selectivity. The probe can effectively cross the blood-brain barrier and show high reactivity in the brains of Alzheimer's disease model mice. In addition, the probe can monitor the Aβ levels in the brains of Alzheimer's disease mice of different ages. It has great potential in the early diagnosis of neurodegenerative diseases.

The application discloses a photosensitizer targeting beta amyloid, and a preparation method and application thereof. The photosensitizer is a photosensitizer with A-D-A configuration, and a structural formula thereof is shown as formula I. The photosensitizer synthesized in the application has a longer emission wavelength, and after being combined with beta amyloid, the fluorescence signal is obviously enhanced, and can effectively generate singlet oxygen, that is, the photosensitizer can target mark A beta protein, and is used for fluorescence imaging of the A beta protein; and after the photosensitizer synthesized in the application is combined with beta amyloid in the brain of an Alzheimer's disease (AD) model mouse, the cognitive ability of the AD mouse can be effectively improved, A beta-mediated neurotoxicity can be reduced, and clearance of A beta plaques can be promoted, that is, the photosensitizer can be used for early diagnosis and treatment of Alzheimer's disease.

The invention relates to the technical field of biomedical engineering, in particular to an invasive mouse electroencephalogram data acquisition and analysis system and method. The system comprises a motion structure assembly used for providing a motion carrier for a mouse and collecting motion parameters; the control assembly is used for adjusting motor output according to the target parameter, generating a synchronous time label instruction, recording the actual motion parameter in real time and storing the actual motion parameter in association with the time label; and the data acquisition and analysis component is used for acquiring original electroencephalogram data, synchronously storing a time label, aligning an electroencephalogram sampling time sequence with a motion control time label sequence, extracting electroencephalogram pulse position information, calculating a neuron discharge frequency and establishing a correlation between the discharge frequency and a motion parameter. According to the technical scheme, accurate and synchronous acquisition, automatic alignment of time stamps and multi-dimensional correlation analysis of mouse motion states and electroencephalogram signals can be realized.

This invention discloses the application of burdock root polysaccharide in the preparation of drugs for treating cognitive impairment, belonging to the field of traditional Chinese medicine technology. Experiments demonstrate that burdock root polysaccharide can improve cognitive impairment and independent exploration ability in D-galactose-induced cognitive impairment model mice, increase superoxide dismutase activity in mouse serum, reduce malondialdehyde content, decrease the content of interleukin-1β and tumor necrosis factor-α in the hippocampus of mouse brains, and alleviate the loss of neurons in the hippocampus of cognitive impairment model mice, thereby achieving a neuroprotective effect and demonstrating a good therapeutic effect on cognitive impairment. This provides a new approach for developing drugs related to the treatment of cognitive impairment.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a respiratory syncytial virus infected mouse model. Disodium clodronate liposome with the concentration of 4ng / mL is injected into the lateral ventricle of the mouse through stereotactic positioning of the brain. 48h after injection, mouse brain tissues are taken to detect the activation state of microglial cells through immunofluorescence and WB, after it is confirmed that the microglial cells are inhibited, RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments are carried out on the mouse, and after the 5th day after virus infection, the mouse is infected by the RSV (virus titer: 2.8 * 10 < 6 > PFU) nasal drop infection experiments. Likewise, mouse brain tissue is taken for virus load detection, and neuropathological changes of the mouse brain tissue are observed through HE staining, immunofluorescence and TUNEL staining, so that the method can be used for constructing a research model of RSV-related nervous system diseases.

This invention discloses a method for preparing NK cells, the NK cells obtained thereby, and their applications. The method includes: sorting NK cells from peripheral blood of an allogeneic donor; culturing them in a serum-free medium containing CD3 monoclonal antibody, CD16 antibody, and IL-2, without the need for a feeder layer; preferably, IL-21 is added for amplification on days 3-5 of culture, and the cells are cultured for 20-40 days. This method yields non-genetically modified NK cells, among which CD56... bright The NK cells comprise >90% of the cell line and highly express a variety of activating and functional molecules. These NK cells effectively clear Aβ oligomers and senescent cells, and alleviate neuroinflammation. In treatment, intracranial injection achieves equivalent or better efficacy with only about 1 / 10th the dose administered intravenously, significantly clearing Aβ deposits in the brains of AD model mice and improving pathology.

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The invention discloses an application of N1, N10-dicaffeoyl spermidine in preparation of a medicine for preventing and treating Alzheimer's disease. Belongs to the technical field of biological medicine. After the N1, N10-dicaffeoyl spermidine is orally taken by an experimental animal, the working memory, the spatial memory and the learning ability of a mouse with Alzheimer's disease (AD) induced by combination of D-galactose and aluminum trichloride can be remarkably improved, the contents of inflammatory factors TNF-alpha, 1L-1beta and 1L-6 of brain tissues of the mouse with AD are remarkably reduced, and meanwhile, the levels of A beta 40 and A beta 42 are remarkably reduced. The N1, N10-dicaffeoyl spermidine is proved to have the effect of improving learning and memory of mice with the Alzheimer's disease, and can be used for preventing and treating neurodegenerative diseases such as the Alzheimer's disease.

The application discloses a kind of mouse brain ischemic lesion automatic quantification method and system based on deep learning, belong to medical image processing and artificial intelligence technical field.The method includes: standardization pretreatment is carried out to T1WI, T2WI, DTI and ASL and other multi-modal MRI data, and enhanced feature tensor is constructed;Lesion intelligent preliminary segmentation is carried out using BA-U-Net network guided by physical prior, and biophysical consistency loss is introduced;Boundary refining is carried out to segmentation result using graph convolution network;Based on LDDMM registration and neural ordinary differential equation model, dynamic evolution modeling is carried out to multi-time point lesion, and severity score is calculated;Finally, comprehensive pathophysiological feature vector is constructed, XGBoost model is used for prediction, and interactive report containing 3D visual model is generated by SHAP explanation.The system includes corresponding functional module.The application realizes high-precision, reproducible automatic quantification to fuzzy lesion, improves the robustness of pathological pattern recognition, and provides dynamic biomarker for drug evaluation.

The invention discloses application of a reagent for detecting an SLC17A7 autoantibody in diagnosis of nervous system diseases. By comparing different fluorescence modes of autoimmune antibodies related to IgG of healthy people in mouse brain tissue slices of patients with nervous system diseases, it is found that fluorescence signals only exist in the patients with nervous system diseases and do not exist in the healthy people, and it is prompted that the patients possibly have the autoimmune antibodies. According to the invention, IgG specific protein related to nervous system diseases is sought through a co-immunoprecipitation technology, a specific SLC17A7 autoantibody is found through cell immunofluorescence (CBA) detection, verification is carried out in cerebrospinal fluid, and finally it is determined that the SLC17A7 autoantibody can be used as a specific marker for diagnosis of nervous system autoimmune diseases. The SLC17A7 is taken as a detection antigen, detection of the expression of the SLC17A7 autoantibody can be applied to a kit for detecting the SLC17A7 autoantibody, the kit can be applied to detection of nervous system diseases, markers for identifying the nervous system diseases are enriched, and the detection accuracy of nervous system related diseases is improved.

The invention discloses a fluorescent / electrochemical dual-mode probe for detecting hydrogen peroxide (H2O2) as well as a preparation method and application of the fluorescent / electrochemical dual-mode probe, and belongs to the technical field of organic probe molecular analysis and detection. The probe takes resorufin (Re) as a fluorescence and electrochemical double-signal report unit and pentafluorobenzenesulfonyl (PS) as an H2O2 response unit, and is named as Re-PS. The preparation process comprises the following steps: under the conditions of nitrogen protection and ice bath, resorufin and pentafluorobenzene sulfonyl chloride react in an anhydrous dichloromethane solvent under the catalysis of triethylamine, and a target product is obtained through rotary evaporation concentration and silica gel column chromatography purification. The probe has both open-type fluorescence detection and ratio-type electrochemical detection functions, and is used for quantitative analysis of H2O2 in Alzheimer's disease (AD) model mouse brain microdialysate. Compared with the existing detection technology, the probe provided by the invention has high stability (37 DEG C, pH 7.4), and the hydrolysis rate lt in 15 min; the method has the advantages of high sensitivity (5%), high selectivity (no obvious response to other active oxygen and biomolecules) and accurate detection (dual-mode signal cross validation and recovery rate of 96.0%-103.0%), provides a reliable tool for accurate detection of H2O2 in biological samples, and has important application value in neurodegenerative disease mechanism research and related diagnosis and treatment evaluation.

This invention proposes a novel fixation device for mouse brain imaging, comprising a first fixation component, an adjustment platform connected to the bottom of the first fixation component, a mounting base plate connected to the bottom of the adjustment platform, and a second fixation component mounted on the mounting base plate, with one end of the second fixation component close to the first fixation component. The first fixation component includes an L-shaped plate mounted on the top of the adjustment platform. Two supporting cylinders are symmetrically arranged on the L-shaped plate near the second fixation component. The top of each supporting cylinder is movably connected to a first connecting plate. A brain fixation plate is connected between the two first connecting plates and fixed to the mouse's head. The brain fixation plate has positioning holes for locating the viewing window area for mouse brain imaging. This device reduces stress response in mice during experiments, improves experimental reliability and repeatability, ensures absolute stability of mice in an awake state, and effectively improves the accuracy of experimental data.

The application provides a construction method and application of a Toxoplasma gondii attenuated strain PruDelta pp2a-c and belongs to the technical field of biological medicine. The TgPP2A-C gene is knocked out to obtain a TgPP2A-C gene deletion Toxoplasma gondii attenuated strain. After the gene is deleted, a large number of starch granules are aggregated between the bodies of the Toxoplasma gondii, and the Toxoplasma gondii loses the ability to form cysts. The in-vitro proliferation speed and pathogenicity of the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain are significantly reduced compared with those of a wild strain. After being infected with the TgPP2A-C gene deletion strain, a mouse does not get ill or die, and no cysts are detected in the brain tissue of the mouse, so the TgPP2A-C gene deletion strain has high safety to a host. After a mouse is immunized with the TgPP2A-C gene deletion Toxoplasma gondii attenuated strain, the antibody level of the mouse is significantly improved, and the mouse can provide significant immunoprotection efficacy against high-dose Toxoplasma gondii RH tachyzoite and Pru cyst re-infection, and can prevent re-infection of Toxoplasma gondii.

The invention discloses an application of a small molecule compound in preparation of a medicine for treating breast cancer. The MEN 10207 is screened through molecular docking analysis, and the capability of the MEN 10207 for remarkably inhibiting proliferation, migration and invasion of breast cancer cells is verified in MDA-MB-231 cells, so that the MEN 10207 has the potential of serving as a breast cancer brain metastasis inhibitor. A further research discovers that the MEN 10207 does not show obvious toxicity in the zebra fish and also shows good tolerance in a mouse intravenous injection test. After the MEN 10207 treats the zebra fish transplanted with the breast cancer cells, the survival and migration capabilities of the breast cancer cells in the zebra fish body are obviously reduced; after the MEN 10207 treats a mouse model with breast cancer brain metastasis, the colonization of breast cancer cells in the mouse brain is also obviously reduced, which proves that the MEN 10207 has the activity of resisting breast cancer brain metastasis in vivo.

The invention discloses an application of circWHSC1 as a biomarker in preparation of a product for diagnosing or treating ineffective recanalization after ischemic stroke. According to the present invention, the circRNA sequencing results show that the expression of the circWHSC1 (including hsacirc0001388 and nucirc0001336) in the ineffective recanalization patient body is significantly reduced, and the circWHSC1 is verified in the mouse brain tissue, the plasma and the thrombus model of the tMCAO model; functional studies show that the circWHSC1 can significantly reduce the cerebral infarction volume of the mouse. The circWHSC1 can be used for early diagnosis, risk assessment, severity judgment, curative effect monitoring and prognosis judgment of invalid recanalization, and can be used as a drug target for screening candidate drugs for preventing or treating invalid recanalization. The invention provides a molecular diagnosis marker and a therapeutic target for invalid recanalization, and has important clinical value.

The invention discloses an NIR-II region fluorescent probe suitable for intrathecal injection, a preparation method of the NIR-II region fluorescent probe and application of the NIR-II region fluorescent probe in cerebrovascular imaging, and belongs to the technical field of probe preparation. The problem of low resolution of current cerebrovascular imaging is solved. The rare earth nano fluorescent material is prepared into the NIR-II region fluorescent probe, delivery of large-size fluorescent imaging particles is achieved through intrathecal injection, and then cerebral vascular imaging is achieved. According to the rare earth nano fluorescent material, NaErF4: x% Ce serves as a fluorescence emission core, NaYF4: y% Yb serves as a fluorescence emission middle layer, NaYF4 serves as a fluorescence emission shell layer, through Er < 3 + > ion self-sensitization, under 808 nm excitation, an NIR-II region fluorescence emission peak of 1525 nm is achieved, NaYF4 serves as an inert shell layer, the luminous intensity of the fluorescent material is further improved, and NIR-II region high-resolution fluorescence imaging of mouse cerebral vessels is achieved in combination with intrathecal injection.